A nested case-control study analyzed data from the French national health care insurance system (SNDS) on individuals with T2D treated with second-line anti-diabetes drugs from 2006 to 2018, reported an increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 agonists after 1–3 years of treatment47. This evidence concerns the gene GCG and diabetes mellitus.